• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

March 1, 2021
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
Pfizer

BioNTech
COVID-19 vaccine COVID-19 first women in the late stages of pregnancy dosed in a clinical trial
AstraZeneca

Oxford University
COVID-19 vaccine COVID-19 initiation of patient enrollment of children age 6 to 17
GlaxoSmithKline

Sanofi
recombinant-protein COVID-19 vaccine with new antigen dosages COVID-19 initiation of phase 2b trial with revamped vaccine
Biophytis Sarconeos (BIO101) acute respiratory failure associated with COVID-19 patient enrollment underway in France and Belgium for part 2 of phase 2/3 trial
PTC Therapeutics PTC299 patients hospitalized with COVID-19 initiation of the second stage of a phase 2/3 trial
Novavax NVX-CoV2373 COVID-19 vaccine completion of patient enrollment in phase 3 trial
Pharma Mar Aplidin (plitidepsin) hospitalized patients with moderate COVID-19 infection approval from the Medicines and Healthcare products Regulatory Agency for UK patients to enroll in phase 3 NEPTUNO trial
Other Trials and Actions
NeoImmuneTech NT-I7 progressive multifocal leukoencephalopathy IND approved by the FDA
Curocell CRC01 relapsed/refractory diffuse large B-cell lymphoma IND approved by the Ministry of Food and Drug Safety of South Korea
Dialco Medical DIMI renal replacement system hemodialysis Investigational Device Exemption (IDE) granted by the FDA
Gala Therapeutics RheOx Bronchial Rheoplasty System chronic bronchitis IDE granted by the FDA
AbFero Pharmaceuticals SP-420 myelodysplastic and myelofibrosis patients with transfusional iron overload initiation of phase 1 trial
LG Chem Life Sciences LG00303174 chronic inflammatory diseases first patient dosed in phase 1 trial
Longeveron Lomecel-B hypoplastic left heart syndrome completion of phase 1 trial
INOVIO INO-4500 DNA vaccine Lassa fever first patient dosed in phase 1b trial
Locus Bioscience LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage Escherichia coli (E. coli) bacteria causing urinary tract infections completion of phase 1b trial
Salarius Pharmaceuticals seclidemstat relapsed and refractory Ewing sarcoma and Ewing-related sarcomas initiation of expansion stage of ongoing phase 1/2 trial
Cartesian Therapeutics Descartes-11 newly diagnosed high-risk multiple myeloma initiation of phase 2a trial
Bridge Biopharma

ML Bio Solutions
BBP-418 limb-girdle muscular dystrophy type 2i first patient dosed in phase 2 trial
Ocuphire Pharma Nyxol and low-dose pilocarpine presbyopia first patients enrolled in phase 2 trial
Stealth Biotherapeutics elamipretide dry age-related macular degeneration with geographic atrophy patient enrollment complete in phase 2 trial
Akero Therapeutics efruxifermin nonalcoholic steatohepatitis initiation of phase 2b trial
The Center for Probe Development and Commercialization [18F]PSMA-1007 diagnostic imaging product targeting prostate-specific membrane antigens initiation of phase 3 trial
Immunocore tebentafusp uveal melanoma Breakthrough Therapy designation granted by the FDA
Dascena GI Bleed Risk Alert System early prediction of gastrointestinal bleeding in adult patients in a hospital setting Breakthrough Device designation granted by the FDA
Regeneron

Sanofi
Libtayo (cemiplimab-rwlc) first-line treatment for advanced nonsmall-cell lung cancer with high PD-L1 expression (?50%) approved by the FDA
EndoClot Plus EndoClot Polysaccharide Hemostatic System management of bleeding during GI procedures approved by the FDA

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing